Other
Liposomal Amphotericin B
0
Pipeline Programs↗
3
Active Trials↗
1
Companies Involved↗
Liposomal Amphotericin B is an early-stage landscape with 0 programs across 1 company. The most active players are Sichuan Huiyu Pharmaceutical Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
10
clinical trials
Completed6 · 60%
Not yet recruiting2 · 20%
Unknown status1 · 10%
Active, not recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Not yet recruiting·—·Phase 3·NCT06525389·428 enrolled
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003938·115 enrolled
Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar
Completed·—·Phase 2·NCT00371995·150 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)